Log in or Sign up for Free to view tailored content for your specialty!
Myeloma News
Value of MRI, lumbar puncture questioned for immune cell-associated neurotoxicity syndrome
MRIs and lumbar punctures may not provide enough therapeutic value to be standard-of-care diagnostic tests in patients suffering neurologic symptoms following chimeric antigen receptor T-cell therapy.
FDA approves earlier use of Carvykti CAR-T for multiple myeloma
The FDA approved ciltacabtagene autoleucel for earlier use in certain adults with relapsed or refractory multiple myeloma.
Log in or Sign up for Free to view tailored content for your specialty!
FDA approves earlier use of Abecma for triple-class exposed multiple myeloma
The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a company release.
‘Spectacular’ accomplishments in multiple myeloma have led to a shift in patient outcomes
Within the past 2 decades, multiple myeloma has shifted from a highly lethal diagnosis to a condition that will no longer shorten the lifespan for many patients.
‘Wake-up call’: Cardiovascular toxicity a concern for patients receiving bispecifics
More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.
Most U.S. cancer trials conducted in more affluent, less diverse areas
Most of the major cancer clinical trial centers in the U.S. are located near more affluent and white populations compared with the national average, according to results published in JAMA Oncology.
FDA panel supports earlier use of two CAR-Ts for multiple myeloma
An FDA advisory committee voted that a pair of chimeric antigen receptor T-cell therapies should be approved for earlier line treatments in adults with relapsed or refractory multiple myeloma, although one produced far more deliberation.
Risk factors identified for secondary leukemia in patients who received CAR T cells
Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.
Those with blood cancers ‘can’t rely on vaccination’ for protection from severe COVID-19
Regardless of vaccination status, individuals with hematologic malignancies had increased odds of developing severe COVID-19 until oral antivirals became widely available in mid-2022, according to data published in JAMA Network Open.
Blenrep regimen extends PFS in advanced multiple myeloma
The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read